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The chloride (Cl−) channel cystic fibrosis transmembrane conductance regulator (CFTR)
is defective in cystic fibrosis (CF), and mutation of its encoding gene leads to various
defects such as retention of the misfolded protein in the endoplasmic reticulum, reduced
stability at the plasma membrane, abnormal channel gating with low open probability,
and thermal instability, which leads to inactivation of the channel at physiological
temperature. Pharmacotherapy is one major therapeutic approach in the CF field and
needs sensible and fast tools to identify promising compounds. The high throughput
screening assays available are often fast and sensible techniques but with lack of
specificity. Few works used automated patch clamp (APC) for CFTR recording, and none
have compared conventional and planar techniques and demonstrated their capabilities
for different types of experiments. In this study, we evaluated the use of planar parallel
APC technique for pharmacological search of CFTR-trafficking correctors and CFTR
function modulators. Using optimized conditions, we recorded both wt- and corrected
F508del-CFTR Cl− currents with automated whole-cell patch clamp and compared the
data to results obtained with conventional manual whole-cell patch clamp. We found
no significant difference in patch clamp parameters such as cell capacitance and series
resistance between automated and manual patch clamp. Also, the results showed good
similarities of CFTR currents recording between the two methods. We showed that
similar stimulation protocols could be used in both manual and automatic techniques
allowing precise control of temperature, classic I/V relationship, and monitoring of
current stability in time. In conclusion, parallel patch-clamp recording allows rapid and
efficient investigation of CFTR currents with a variety of tests available and could be
considered as new tool for medium throughput screening in CF pharmacotherapy.
Keywords: CFTR, automated patch clamp, medium throughput assay, physiological temperature recording,
current stability
INTRODUCTION
The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP-dependent chloride
(Cl−) channel whose encoding gene is mutated in the common autosomal recessive disease cystic
fibrosis (CF; Riordan et al., 1989). Mutations of the CFTR gene have been grouped into six classes
according to their effects on synthesis, maturation, and function of the CFTR protein. The most
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common CFTR mutation is the deletion of the phenylalanine
508 residue (F508del-CFTR), a mutation present on at least
one allele in ∼90% of patients with CF. The F508del mutation
induces misfolding of the nascent protein and retention in the
endoplasmic reticulum (Cheng et al., 1990), reduced stability at
the plasma membrane (Lukacs et al., 1993), abnormal channel
gating with low open probability (Dalemans et al., 1991), and
thermal instability, which leads to inactivation of the channel at
physiological temperature (Wang et al., 2011; Liu et al., 2012).
Cystic fibrosis transmembrane conductance regulator
pharmacotherapy is one major therapeutic strategy that involves
identifying compounds that correct abnormal CFTR protein.
Most research effort is directed at finding small molecules
which interact directly with mutated CFTR to correct its
folding and gating, and thus improve protein trafficking and
channel function. Two compounds that have yielded promising
results are the potentiator Ivacaftor, also called VX770 (Van
Goor et al., 2009), which was approved by the Food and Drug
Administration (FDA) in 2012 as KalydecoTM for patients over
12 years of age carrying the G551D mutation (5% of patients),
and the corrector Lumacaftor, also called VX809 (Van Goor et al.,
2011). Lumacaftor was approved for clinical use in combination
with Ivacaftor for the treatment of F508del homozygous patients;
however, this combination therapy, called OrkambiTM, provided
only modest benefit (Boyle et al., 2014) indicating that more
efficacious correctors are still needed. Therefore, the search for
innovative small molecules and understanding their mechanisms
of action remain a priority for CF therapeutic research. To this
end, robust screening assays are essential for rapidly testing
large numbers of compounds and performing informative
concentration–response curves in vitro. As multiple CFTR
defects need to be corrected, cell-based assays should monitor
improvements in the trafficking, membrane stability, and
channel function of rescued mutant CFTR.
One of the most powerful techniques for characterizing
ion channels and studying their pharmacology is patch clamp
recording. It allows the recording of channel currents in real time,
in a biological environment, and with high resolution (Hamill
et al., 1981). Unlike other functional assays such as Ussing
chamber short-circuit current measurements, flux studies (using
either radioisotopes or ion-selective electrodes), or fluorescence
assays [membrane potential detection (Van Goor et al., 2006;
Maitra et al., 2013) or yellow fluorescent protein (YFP) quenching
(Galietta et al., 2001; Pedemonte et al., 2011)], patch clamping
provides precise and complete electrophysiological information
on ion channel function. Although conventional manual patch
clamp (MPC) techniques have low throughput and are therefore
not suitable for screening phase, automated patch clamp (APC)
techniques are available and can be applied to investigate CFTR
pharmacology.
Parallel planar APC provides a “medium throughput
screening” technique with higher resolution than other
screening methods and provides quantitative information on the
electrophysiological properties of ion channels more rapidly than
MPC (Farre et al., 2009). APC has become the gold standard for
early safety assessment when examining cardiac hERG channel
to new drug candidates (Polonchuk, 2012) but has not yet been
widely used for CFTR pharmacology studies (Liu et al., 2009;
Jacobsen and Sørensen, 2016; Brüggemann et al., 2017).
The objective of this study is to describe the application
of APC technology to CFTR pharmacology. We recorded
wt- and F508del-CFTR currents using planar APC under various
conditions and compared the results with those obtained with
MPC method.
MATERIALS AND METHODS
Cell Culture
Baby Hamster Kidney (BHK) cells were cultured in
DMEM/F12 medium supplemented with 5% FBS and 1%
Penicillin/Streptomycin. To study CFTR current, BHK were
stably transfected with pNUT-wt-CFTR or pNUT-F508del-
CFTR plasmids using JetPeI reagent (Polyplus, Illkirch, France)
according to the manufacturer’s instructions. Clones were
selected by addition of methotrexate (500 µM) and CFTR
expression validated by immunoblotting.
Chinese hamster ovary (CHO), HeLa, and CFBE41o [Cystic
Fibrosis Bronchial Epithelial (CFBE)] cells were cultured as
previously described (Kunzelmann et al., 1993; Grygorczyk
et al., 1996; Hinzpeter et al., 2010). The CFBE cells developed
in the laboratory of D. Gruenert had been transduced with
wt- or F508del-CFTR containing the M470 polymorphism by
Transzyme (Birmingham, AL, USA) and were kindly provided JP
Clancy (Cincinnati Children’s Hospital Medical Center).
Cells were cultured at 37◦C in 5% CO2 and were plated in
8.8 cm2 dishes for MPC and 21.6 cm2 dishes for APC. Patch-
clamp experiments were performed 2–3 days after plating. APC
needs cells in suspension, therefore, cells at 70–80% confluence
were detached by incubation with Accutase (EMD Millipore,
Billerica, MA, USA) for 5 min at 37◦C, suspended in complete
culture, centrifuged for 2 min at 1000 rpm, and resuspended
in DMEM/F12 without serum. Prior to use, the suspension was
placed at 37◦C for 15–20 min to allow cells to recover from the
detachment process.
Patch Clamp Experiments
For conventional MPC, Cl− currents were measured in
the whole-cell patch-clamp configuration after compensating
electronically for pipette capacitance in the cell-attached mode.
Voltage-clamp signals were recorded using an Axopatch 200B
amplifier connected to an analog/digital interface, Digidata
1440A, and were analyzed using pCLAMP 9 software (all from
Axon Instruments Inc., Burlingame, CA, USA). Pipettes were
pulled from borosilicate glass capillaries (GC150-TF10; Clark
Electromedical Inc., Reading, UK) and connected to the head
stage of the patch clamp amplifier through an Ag–AgCl wire. The
resistance of pipettes in the bath solution ranged between 4 and
6 M.
Automated whole-cell patch clamp recordings were obtained
using two different systems. Most experiments were performed
on the eight-channel Patchliner R© NPC-16 workstation (Nanion
Technologies GmbH, Munich, Germany), which was coupled
to two QuadroEPC-10 amplifiers (HEKA Elektronik GmbH,
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Germany). APC procedures followed Nanion’s standard
procedures and used Nanion’s high-resistance chips. Some
experiments were also performed using the Qpatch R© 16X system
(Sophion Bioscience, Ballerup, Denmark) with single-hole
Qplates. Both chip models exhibited a resistance of 3–3.5 M.
Similar experiments were performed using APC and MPC.
The holding potential was maintained at −40 mV throughout
the experiment, and two voltage-clamp protocols were used to
measure whole-cell CFTR currents. Figure 1 shows the sequence
of events (called tree) used on the Nanion software (Figure 1A)
and protocols applied for CFTR recording (Figure 1B). The tree
of events shows all steps leading to the whole-cell configuration
(gray rectangle 1) followed by the CFTR recording parameters
(gray rectangle 2). The current–voltage (I–V) relationship (I/V
protocol, blue dots) was determined by pulsing from the holding
potential of −40 mV to test potentials between −80 and
+80 mV increasing in 20 mV increments. To monitor the current
evolution under drugs application and confirm the absence of
significant leak current; a single depolarization from−40 to 0 mV
was applied every 5 s for 6–7 min (drug time course protocol,
green dots).
Medium and Chemicals
Similar external and internal solutions were used for MPC and
APC. The external bath solution contained (in mM): 145 NaCl,
4 CsCl, 1 CaCl2, 1 MgCl2, 10 glucose, and 10 TES titrated
with NaOH to pH 7.4. The osmolarity of the bath solution
was 315 ± 5 mOsmol. The intrapipette solution contained
(in mM): 113 L-aspartic acid, 113 CsOH, 27 CsCl, 1 NaCl, 1
MgCl2, 1 ethylene glycol tetraacetic acid (EGTA), 10 TES, and 3
MgATP titrated to pH 7.2 with CsOH. Osmolarity of the pipette
solution was 285 ± 5 mOsmol. To facilitate giga-ohm (G) seal
obtaining with the Patchliner R© system, the external solution was
transiently replaced by a seal enhancer solution during the sealing
procedures. The seal enhancer solution contained (in mM): 80
NaCl, 3 KCl, 10 MgCl2, 35 CaCl2, and 10 Hepes (Na+ salt)
titrated with HCl to pH 7.4. Osmolarity of the seal enhancer
solution was 298 ± 5 mOsmol. After stable sealing of the cell,
the seal enhancer solution was replaced by the external solution
before performing the whole-cell configuration and recordings.
Recordings were performed at room temperature (20–25◦C)
unless stated otherwise.
VX809 and VX770 were from Selleckchem (Houston, TX,
USA) and CFTRinh-172 was from Calbiochem (San Diego, CA,
USA). All other products were from Sigma–Aldrich (Saint-
Quentin-Fallavier, France). Stock solutions were prepared in
dimethylsulfoxide.
Analysis and Statistics
Manual patch clamp results were analyzed with pCLAMP, version
9, software (Axon Instruments). APC results were analyzed with
Patch MasterPro software (HEKA) for Patchliner R© experiments
FIGURE 1 | Experimental procedure for automated patch clamp (APC) cystic fibrosis transmembrane conductance regulator (CFTR) recording.
(A) Tree of events for whole-cell configuration establishing (gray rectangle 1) and personalized CFTR recording (gray rectangle 2). (B) The two different protocols
applied for CFTR recording: I/V protocol (blue dots) for current/voltage relationship visualization and drug time course (green dots) protocol to monitor the effect of
compound in time.
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and with Sophion Analyzer Software (Sophion Bioscience) for
Qpatch R© experiments.
Results are expressed as means ± SE of n observations.
Data were compared using the Student’s t-test. Differences were
considered statistically significant at p < 0.05. All statistical tests
were performed using GraphPad Prism, version 6.0 (GraphPad
Software).
RESULTS
Evaluation of APC Whole-cell Recording
Conditions
Automated planar patch clamp is commonly used to detect off-
target effects on the potassium channel hERG during the safety
testing phase of drug development. Here, we describe its use for
recording currents carried by wt-CFTR and rescued F508del-
CFTR channels and compare the results with those obtained
from MPC recordings. In this study, we tested two APC devices:
the Patchliner R© from Nanion and the Qpatch R© from Sophion
Bioscience.
Both systems tested use the general principle of planar patch
clamp, which is comparable to MPC with some differences
in the experimental conditions (Milligan et al., 2009). Briefly,
planar APC experiments use cartridge chips with a variable
number of microfluidic chambers. Each chamber consists of two
compartments containing extra- and intrasolutions, separated by
a planar substrate (borosillicate glass for the Patchliner R©, silicon-
based glass for the Qpatch R©) that has a micron-sized aperture.
Cells in suspension are placed in the wells and interact with
the glass to form stable giga-seal at the aperture. After giga-
seal formation, whole-cell configuration is achieved by physical
rupture of the cell-attached patch, then pre-programmed voltage-
clamp steps are applied and recording begins. Both systems used
the microfluidic technology but with the following differences:
Patchliner R© chips allow perfusion of external and internal
solutions while Qpatch R© has no internal perfusion. Another
major difference is the higher throughput of the Qpatch R©, which
possesses one or two arms, each with four channels, while the
Patchliner R© has only a single pipetting arm with one channel (see
for review, Dunlop et al., 2008).
As APC requires both fresh cell suspension and cell membrane
integrity, the first step was to obtain viable and isolated cells in
suspension. We tested the BHK, CHO, HeLa, and CFBE cell lines
and several detachment protocols and reagents (e.g., Trypsin–
EDTA, Accutase). The best quality cells in suspension were
obtained using Accutase and the detachment protocol detailed
above in the Section “Materials and Methods.” For all the tested
cell lines, we achieved 90% cell viability (estimated by a manual
counting of Trypan blue-stained cells) and well-separated cells
without clusters.
Whole-cell-recording parameters and success rate for each cell
line obtained with the Patchlinerx R© system are shown in Table 1
along with the number of experiments that reached our criteria
for a successful recording: a seal resistance of 1 G (Rm), whole-
cell access with a series resistance <20 M (Rs), and a complete
recording sequence (i.e., basal conditions – CFTR activation –
CFTR inhibition). Success rates varied between cell lines. The
rates of achieving seals, entering the whole-cell configuration,
and completing the CFTR recording protocol are shown in the
table, with the overall success rates in pooled wt- and F508del-
CFTR experiments of 31.1 and 25.6% in BHK and CHO cell
lines, respectively. Much lower rates were obtained in CFBE
epithelial cells (5.2%), although this might be improved with
further optimization of the protocol. The following discussion
focuses mainly on results obtained with BHK cells.
Planar APC Recording of wt-CFTR
Recordings were collected and analyzed in experiments that met
the above criteria. In the following experiments, voltage pulse
protocols were applied under basal conditions, in presence of the
activator cocktail containing 10 µM Forskolin (Fsk) + 30 µM
Genistein (Gst) and after further addition of 10 µM CFTRinh172,
a relatively selective CFTR inhibitor when added acutely (Ma
et al., 2002). Briefly, Fsk regulates CFTR activity by stimulation of
adenylate cyclase leading to the elevation of cAMP (Seamon and
Daly, 1981) and PKA phosphorylation of the CFTR regulatory
domain (R domain) (Tabcharani et al., 1991; Berger et al., 1993).
The isoflavone Gst is a potent potentiator of the wt and F508del-
CFTR (Hwang et al., 1997).
Figure 2A shows representative whole-cell currents recorded
in BHK-wt-CFTR cells using both Patchliner R© automatic (left
traces) and conventional (right traces) methods. Figure 2B shows
the corresponding I/V relationships. With the two experimental
methods, Fsk + Gst elicited a robust Cl− current that was
almost abolished by the specific inhibitor CFTRinh172. However,
the current density recorded by APC with Fsk + Gst was
larger than the one recorded by MPC (respectively, at +60 mV
TABLE 1 | Success rates of cystic fibrosis transmembrane conductance regulator (CFTR) recording with automated patch clamp (APC) experiments on
Patchliner system.
Cell line Number of channel Rm > 1 G Whole cell (Rs < 20 M) Recording %Success
Baby Hamster Kidney (BHK) 87 60 51 27 31.1
Chinese hamster ovary (CHO) 86 48 39 22 25.6
HeLa 133 71 57 18 13.5
Cystic Fibrosis Bronchial Epithelial (CFBE) 38 5 3 2 5.2
Average recording parameters and success rates. Number of channel represents the number of experiment starting; Rm > 1 G: number of cells reaching the giga seal;
Whole-cell: number of whole-cell configuration obtained with a series resistance (Rs) <20 M; Recording: number of experiments with a complete recording sequence
(basal – activation – inhibition).
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FIGURE 2 | Cystic fibrosis transmembrane conductance regulator whole-cell recording by automated and manual patch clamp from BHK-wt-CFTR.
(A) Representative traces of whole-cell Cl- currents recorded by APC (left traces) or manual patch clamp (MPC; right traces) by stepping from a holding potential of
−40 mV to a series of test potentials from −80 to +80 mV in 20 mV increments under basal (unstimulated) conditions or in the presence of 10 µM Fsk + 30 µM Gst
or 10 µM CFTRInh 172 as indicated. Dashed lines indicate the zero current level. (B) Corresponding current densities (pA/pF) obtained by current–voltage
relationships normalized by cell capacitance for APC (left traces; n = 11) and MPC (right traces; n = 6). (C) Corresponding distribution of current densities recorded
at 0 mV. Error bars, SEM.
343.4 ± 52.8 pA/pF n = 11 and 227.4 ± 45.5 pA/pF n = 6;
p = 0.16) and displayed slight rectification and a reversal
potential shift to −20 mV from the theoretical ECl− , which is
expected to be near −40 mV. Several observations suggest that
the differences observed between data obtained using APC and
MPC were caused by a decrease in the seal resistance while
recording.
First, there were no differences when we compared the
cell capacitance (Cm) and series resistance obtained with each
method (p= 0.46 for Cm and p= 0.09 for Rs; Table 2) suggesting
the current density obtained with APC was not increased
artificially due to underestimation of the cell capacitance or
reduced access resistance to the inside of the cell. Comparing the
current densities at +60 mV under control conditions revealed
a significant difference between basal currents measured under
APC and MPC conditions (32.3 ± 6.3 pA/pF n = 11 and
2.4 ± 0.4 pA/pF, n = 6, p = 0.003, respectively) and basal
conductance was not sensitive to CFTRinh172 suggesting it was
not mediated by CFTR (data not shown). By contrast, at 0 mV
(where the non-selective leak current would be undetectable),
TABLE 2 | Comparison of patch clamp parameters for manual and
automated BHK whole-cell recordings.
Automated patch clamp
(APC)
Manual patch clamp
(MPC)
Cm (pF) Rs (M) Cm (pF) Rs (M)
BHK-wt-CFTR 17.6 ± 5.0 18.9 ± 2.5 23.1 ± 2.8 12.4 ± 1.4
BHK-F508del-CFTR 16.4 ± 2.7 10.3 ± 1.3 17.9 ± 1.6 13.0 ± 1.4
Mean of recorded parameters for complete experiment on BHK–CFTR (wt
and F508del) obtained by APC (on Patchliner) or manual patch clamp (MPC);
Cm: membrane capacitance; Rs: series resistance. Values are expressed as
mean ± SEM.
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FIGURE 3 | Cystic fibrosis transmembrane conductance regulator whole-cell recording by automated and MPC from corrected (VX809 24 h)
BHK-F508del-CFTR. (A) Current densities (pA/pF) obtained by current–voltage relationships normalized by cell capacitance on BHK-F508del-CFTR corrected 24 h
with 10 µM VX809. Whole-cell Cl- currents are recorded by APC (left traces; n = 16) or MPC (right traces; n = 7) by stepping from holding potential of −40 mV to a
series of test potentials from −80 to +80 mV in 20 mV increments under basal (unstimulated) conditions or in the presence of 10 µM Fsk + 30 µM Gst or 10 µM
CFTRInh 172 as indicated. (B) Corresponding distribution of current densities recorded at 0 mV. Error bars, SEM.
current densities recorded in the presence of Fsk + Gst were
similar for both methods (76.4 ± 12.9 pA/pF, n = 11 with APC
and 80.5± 14.7, n= 6 with MPC; n.s. p= 0.85; Figure 2C).
APC Recording of Corrected
F508del-CFTR
F508del is by far the most common CF mutation; therefore,
the functional screening assay should enable the recording of
F508del-CFTR currents. However, this mutation induces a gating
defect in addition to the trafficking defect (Dalemans et al., 1991);
therefore, the assay should be sensitive enough to accurately
record potentiator-induced increases in Cl− current so that
different potentiator and corrector drugs can be compared.
In another set of experiments, we compared F508del-CFTR
current recordings obtained with the APC (Patchliner R©) and
MPC methods.
First, we used BHK-F508del-CFTR cells under control
conditions (DMSO treatment for 24 h). As expected, whole-
cell recording detected little for any Cl− current using either
method (current densities at 0 mV: −0.67 ± 1.1 pA/pF, n = 10
with APC and 6.9 ± 2.9 pA/pF, n = 6 with MPC; data not
shown). When the same experiments were performed after a 24-h
pretreatment with the corrector VX809 (10 µM), CFTR current
was detected. Figure 3A shows I/V relationships obtained using
APC (left curves) and MPC (right curves) under basal conditions
and during CFTR activation and inhibition. Figure 3B shows
the corresponding distribution of each current density at 0 mV.
As with wt-CFTR, Fsk + Gst elicited large F508del-CFTR
currents that were nearly abolished by CFTRinh172 and, as
previously observed, the APC current densities were somewhat
larger and the reversal potential were shifted compared to MPC.
Despite these differences, electrophysiological parameters were
not significantly different (Table 2; p = 0.73 for Cm and p = 0.24
for Rs) nor were the current densities at 0 mV (Figure 3B;
27.70 ± 4.9 pA/pF, n = 16 for APC and 39.62 ± 9.3 pA/pF,
n = 7 for MPC, p = 0.23). Taken together, these results indicate
that, aside from a slight contamination by leak current with
APC, similar results can be obtained when recording rescued
F508del-CFTR using either method.
Variety of Recording Applications
The recording sequence above is useful when determining the
efficiency of candidate corrector molecules or comparing the
potencies of several correctors. However, with MPC, we are
potentially able to collect information such as the stability of
currents over long time periods and the temperature dependence
of channel gating. We examined the capabilities of APC for such
experiments with Patchliner R© system (Figure 4).
To study the stability of whole-cell currents, we performed
APC whole-cell recordings on BHK cells over a 20-min period.
Figure 4A shows the mean of wt-CFTR Cl− current time courses
in the presence of Fsk + Gst (n = 5). For these experiments,
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FIGURE 4 | Alternative application recorded with APC. Means of whole-cell Cl- current density time courses at 0 mV recorded on BHK-wt-CFTR (A,B) or
BHK-F508del-CFTR (C) by APC. (A) Monitoring of wt channels rundown by long recording in presence of 10 µM Fsk + 30 µM Gst (n = 5). (B) Monitoring CFTR
potentiation by sequential addition of 1 µM Fsk, and then 10 µM VX770 (n = 8). Black lines are representative linear regressions of the time course curves before and
after potentiator addition. Means of slope values are indicated. (C) Effect of temperature on F508del channel function: recording of whole-cell current at room (RT;
n = 6) or physiological temperature (35◦C; n = 5) in presence of 10 µM Fsk + 30 µM Gst. For all conditions, 10 µM CFTRinh172 was added at the end of experiment.
Colored symbols are the mean of current densities and gray dashed lines the corresponding error, SEM.
Rs were determined at the beginning and end of each recording
and did not vary more than 25% from the initial value. As for
MPC, we can record long enough with APC to observe the
physiological rundown of CFTR channels (Becq et al., 1994).
Such an experiment may be considered when assaying the ability
of compounds to increase CFTR stability. In addition, the high
quality of the seal and stability of the patch may allow the
effects of sequential drug applications to be monitored and
determination of EC50 or IC50. Figure 4B shows the mean of wt-
CFTR current time courses at 0 mV with sequential addition of
sub-maximal Fsk (1 µM) followed by 10 µM VX770 (n = 8).
To evaluate the potentiator effect of the tested compound, linear
regression analyses were performed using the points on each time
course curve. For each individual experiment, points during the
2 min before and the 2 min after compound addition were used
to calculate the slopes. The example in Figure 4B (black lines)
shows representative linear regression before and after addition
of VX770. Here, the mean slopes computed for eight different
cells yielded values that are significantly different (0.101 ± 0.031
for Fsk alone and 0.499 ± 0.149 after 10 µM VX770 addition,
n = 8, p = 0.02) and clearly demonstrate potentiation of the
Fsk-activated current by the potentiator VX770.
Finally, the temperature dependence of F508del CFTR
function was examined using APC. Whole-cell recordings were
obtained at room temperature and at 35◦C using BHK-F508del-
CFTR cells that had been pretreated for 24 h with 10 µM
VX809. Figure 4C shows the mean of current densities at
0 mV during stimulation of F508del-CFTR by Fsk + Gst at
22◦C (n = 6) or 35◦C (n = 5). According to the literature
(Wang et al., 2011, 2014; Liu et al., 2012) and contrary to the
CFTR response obtained at 22◦C, only a small transient current
is recorded at physiological temperature. These results show
that whole-cell CFTR currents can be studied at 37◦C using
APC, allowing drug effects to be studied under physiological
conditions. Also, it suggests the feasibility of screening for
compounds that correct the thermal instability of F508del-
CFTR.
Planar APC Using Other Cells and
Robotic Systems
The experiments described above were performed using BHK
cells and the Patchliner R© APC system. However, as mentioned in
Table 1, we also tested APC with different cell types. Figures 5A,B
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FIGURE 5 | Cystic fibrosis transmembrane conductance regulator whole-cell recording by automated and MPC from Chinese hamster ovary (CHO)
cells stably expressing wt-CFTR. (A–C) Current densities (pA/pF) obtained by current–voltage relationships normalized by cell capacitance on CHO-wt-CFTR.
Whole-cell Cl- currents are recorded with MPC (A, n = 4) or with APC with two workstations: the Nanion Patchliner (B, n = 10) or the Sophion Qpatch (C, n = 60) by
stepping from a holding potential of −40 mV to a series of test potentials from −80 to +80 mV in 20 mV increments under basal (unstimulated) conditions or in the
presence of 10 µM Fsk + 30 µM Gst or 10 µM CFTRInh 172 as indicated. (D) Histograms of current densities recorded at 0 mV in the presence of Fsk + Gst. Error
bars, SEM; ns, not significant.
show I/V relationships obtained using MPC or APC to study
CHO cells stably expressing wt-CFTR. Cells were recorded under
basal conditions and in the presence of 10 µM Fsk + 30 µM
Gst and 10 µM CFTRInh 172. With both methods, the activator
cocktail Fsk+Gst, elicited strong voltage- and time-independent
currents that were nearly abolished by CFTRinh172. A small
shift in the reversal potential was observed with APC (−20 mV
instead of the expected −40 mV); nevertheless, robust CFTR
recordings were obtained with CHO cells stably expressing wt-
CFTR, which resembled those obtained with BHK except for
having lower current densities as expected with lower CFTR
expression.
Finally, we tested CFTR recording using another robotic APC
system: the Sophion QPatch R©. Using QPatch R©, the rates of success
obtained were better for CHO-wt-CFTR cells, and the CFTR
whole-cell recordings made with the same protocols and medium
were close to those obtained previously (Figure 5C).
In summary, detailed comparison of the current densities at
0 mV using the MPC or two APC systems suggests they yield very
similar results (Figure 5D; I (pA/pF) at 0 mV: 29.37± 4.4 pA/pF,
n = 10 for the Patchliner R©; 28.04 ± 1.9 pA/pF, n = 60 for
Qpatch R© and 26.40 ± 3.6 pA/pF, n = 4 for MPC) and provide
good reproducibility between different APC systems and cell
models.
DISCUSSION
Several cell-based screening assays for CFTR are available that
monitor anion flux [e.g., using radiotracer eﬄux (Venglarik
et al., 1990) or YFP-based halide transport (Galietta et al.,
2001)]. Although they provide high throughput, they are only
semi-quantitative because the net electrochemical across the
membrane for the anion changes during the course of the
assay. Here, we have shown that planar APC can be used
when screening for CFTR modulators and provides medium
throughput together with several advantages over other cell-
based assays.
APC allows wt- and corrected F508del-CFTR activity to be
recorded with high efficiency and resolution approaching that
of MPC, but at much faster rates. Optimizing the success rate is
key to using these assays for drug testing. In the present study,
success rates reached 31% for BHK and 25.6% for CHO cells,
which are acceptable though values lower than that were found
in the literature for similar cell lines and the same APC system
(Milligan et al., 2009). To increase this rate of experiment success
and develop the use of more physiological cell lines (i.e., CFBE
and Calu-3), the cell preparation needs to be improved, e.g., by
adapting protocols for culturing adherent cell lines in suspension
(Muller et al., 2005).
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CFTR recordings obtained using APC are similar to those
obtained using MPC: no CFTR current was detected under
basal conditions but it was strongly activated by Fsk + Gst
and abolished by the specific CFTR inhibitor CFTRinh172. The
main difference was that CFTR currents recorded using APC
were often contaminated with non-selective leak currents due
to a decline in seal quality. Since the user can’t easily intervene
during the APC experiments, they require controls and well-
designed protocols to allow the discrimination of false positives.
In our experiments, we replaced potassium ions with cesium to
block K+ currents and designed patch solutions with an ECl−
far from 0 mV so that leak and CFTR currents could be easily
discriminated.
Interestingly, APC can use the same protocols as MPC,
making it useful for studies of current stability over long periods,
the effects of sequential drug applications (useful for EC50
or IC50 determination, precise measurement of potentiation),
and the temperature dependence of channel gating CFTR
modulators. This last point is a real advantage compared to
many HTS assay since it enables compounds to be tested
at physiological temperature. As already mentioned, mutant
CFTR channels have altered temperature sensitivity, yet, most
screening assays are performed at room temperature, which may
explain some discrepancies between in vitro results and clinical
trials. Similar results were obtained using the two APC systems
suggesting either planar APC methods can be used for CFTR
studies.
Once the conditions have been optimized, APC is faster and
easier to use than MPC with similar high-resolution results and
the possibility to address the same questions. All steps during
APC experiments are finely controlled and executed by a robot,
allowing more consistent times and concentrations at which
drugs are injected. The use of microfluidics within the APC chips
ensures that volumes are minimized and allows more precise
control of the temperature.
A major drawback with APC is the requirement for cells
in suspension, which limits the use of epithelial cell lines
under physiological conditions, including CFBE, Calu-3, and the
human colonic cell line T84. The normal state of these cells
is highly polarized, with tight junctions and apical CFTR. The
effects of CFTR modulators may be influenced by the integrity of
the epithelium and the maintenance of cell–cell contacts (Fritsch
and Edelman, 1996). The detachment protocol used in this study
or the generation of cell lines adapted to suspension, may also
adversely affect interactions between CFTR and its partners,
altering channel function and regulation.
CONCLUSION
We have shown that whole-cell parallel planar APC is suitable
for recording CFTR activity and gives robust results similar
to those obtained by MPC but with higher throughput and
standardized protocols. Screening with APC is an attractive
option for pharmacological investigations including hit
validation, trafficking correction, potentiation, thermal stability
restoration, and the functional characterization of mutant CFTR.
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